JP2005523335A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523335A5
JP2005523335A5 JP2003587405A JP2003587405A JP2005523335A5 JP 2005523335 A5 JP2005523335 A5 JP 2005523335A5 JP 2003587405 A JP2003587405 A JP 2003587405A JP 2003587405 A JP2003587405 A JP 2003587405A JP 2005523335 A5 JP2005523335 A5 JP 2005523335A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
antibody consisting
antibody
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2003587405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/010473 external-priority patent/WO2003090772A1/en
Publication of JP2005523335A publication Critical patent/JP2005523335A/ja
Publication of JP2005523335A5 publication Critical patent/JP2005523335A5/ja
Ceased legal-status Critical Current

Links

JP2003587405A 2002-04-25 2003-04-17 高齢被検体の不安障害および気分障害の治療方法 Ceased JP2005523335A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37546202P 2002-04-25 2002-04-25
PCT/US2003/010473 WO2003090772A1 (en) 2002-04-25 2003-04-17 Method for treating anxiety and mood disorders in older subjects

Publications (2)

Publication Number Publication Date
JP2005523335A JP2005523335A (ja) 2005-08-04
JP2005523335A5 true JP2005523335A5 (https=) 2006-06-01

Family

ID=29270644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587405A Ceased JP2005523335A (ja) 2002-04-25 2003-04-17 高齢被検体の不安障害および気分障害の治療方法

Country Status (9)

Country Link
US (1) US20050129691A1 (https=)
EP (1) EP1501531B1 (https=)
JP (1) JP2005523335A (https=)
AT (1) ATE419871T1 (https=)
AU (1) AU2003223474B2 (https=)
CA (1) CA2483729A1 (https=)
DE (1) DE60325717D1 (https=)
ES (1) ES2318123T3 (https=)
WO (1) WO2003090772A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
WO2006066118A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
NZ574188A (en) * 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2121754E (pt) 2007-01-18 2015-05-11 Lilly Co Eli Fab de beta-amilóide peguilado
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2170389T3 (pl) * 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
RS53174B (sr) * 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO2000077178A1 (en) * 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
BRPI0108676B8 (pt) * 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US7166478B2 (en) * 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses

Similar Documents

Publication Publication Date Title
JP2005523335A5 (https=)
Calhoun et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid
Díaz-Moreno et al. Noggin rescues age-related stem cell loss in the brain of senescent mice with neurodegenerative pathology
Kastanenka et al. Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice
Wu et al. LINGO‐1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5 XFAD mice
JP2005500389A5 (https=)
WO2004091510A3 (en) Recombinant il-9 antibodies and uses thereof
WO2008067464A3 (en) NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
ATE461941T1 (de) Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
DE60229051D1 (de) Humanisierte antikörper
Villa et al. The synergistic relationship between Alzheimer’s disease and sleep disorders: an update
ATE425965T1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
JP2008501758A5 (https=)
Zhang et al. Triggering receptor expressed on myeloid cells 2 overexpression inhibits proinflammatory cytokines in lipopolysaccharide‐stimulated microglia
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
Pauwels et al. Parkinson’s disease: a tale of many players
TR200002626T2 (tr) Terkip
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
Kalampokini et al. Restless legs syndrome due to brainstem stroke: A systematic review
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
Romano et al. Genotype–phenotype spectrum and correlations in Xia‐Gibbs syndrome: Report of five novel cases and literature review
JP2009178162A5 (https=)
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen